Form 4: Biogen Director Monish Patolawala Receives Stock Grant

Biogen Inc. director Monish D. Patolawala was granted 1,505 restricted stock units as part of his director compensation.

Summary

• Director Monish D. Patolawala acquired 1,505 restricted stock units (RSUs) of Biogen Inc. common stock.
• The transaction occurred on June 9, 2026.
• The shares were granted at a price of $0, representing equity-based compensation.
• Following this transaction, the director's total beneficial ownership is 5,215 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's interests with those of shareholders through equity ownership.

Negatives

• None identified.

Risks

• The value of the equity grant is subject to market fluctuations in Biogen's share price.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date (June 9, 2027).

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for large-cap pharmaceutical and biotech companies.
• The vesting schedule aligns with typical annual director compensation cycles observed at peers like Amgen or Gilead Sciences.

Stakeholder Impact

• Shareholders: Minimal impact; represents standard director compensation.

Next Steps

• Vesting of the 1,505 restricted stock units upon the next annual meeting or June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Director, Insider Trading, Form 4, Equity Compensation